Irritable Bowel Syndrome News

The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of functional constipation in patients aged 6 to17 years old, according to an Ironwood Pharmaceuticals press release.

Celltrion has submitted a biologics license application to the FDA for the consideration of a subcutaneous formulation of infliximab in the treatment of inflammatory bowel disease, according to a press release.

Specific and nonspecific acupoint acupuncture improved symptoms of diarrhea among a small subset of patients with irritable bowel syndrome, according to results from a pilot study reported in JAMA Network Open.

Irritable bowel syndrome may result from ineffective anatomical, physiological and neuropsychological gravity-management systems, a researcher theorized in an article published in The American Journal of Gastroenterology.

Chronic constipation affects up to 20% of adults and 16% of children in the U.S, therefore the International Foundation for Gastrointestinal Disorders recognized December as Constipation Awareness Month.

AbbVie announced that it has submitted a supplemental new drug application for Linzess for the treatment of functional constipation in patients aged 6 to 17 years, according to a press release.

The FDA has approved Idacio as the eighth biosimilar to adalimumab, for all eligible indications of the reference product, clearing the way for its U.S. release in 2023 alongside a deluge of other Humira biosimilars.

Disorders of gut-brain interaction cause symptoms throughout the digestive tract including pain, changes in bowel patterns, nausea, regurgitation or vomiting, which can be upsetting or embarrassing for children and teens

CHARLOTTE, N.C. — Once daily plecanatide effectively relieved symptoms in patients of varying age with chronic idiopathic constipation and irritable bowel syndrome-constipation, according to a poster at the ACG Annual Scientific Meeting.

CHARLOTTE, N.C. — Daily treatment with Xifaxan over 2 weeks improved stool consistency and fecal urgency in adults with irritable bowel syndrome-diarrhea, according to a poster at the ACG Annual Scientific Meeting.